Literature DB >> 22595047

Sipuleucel-T for the treatment of advanced prostate cancer.

Mark W Frohlich1.   

Abstract

Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response to prostate cancer that prolongs the overall survival of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC). The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented. The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22595047     DOI： 10.1053/j.seminoncol.2012.02.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  11 in total

Review 1.  Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.

Authors:  Emma L Simpson; Sarah Davis; Praveen Thokala; Penny R Breeze; Peter Bryden; Ruth Wong
Journal:  Pharmacoeconomics       Date:  2015-11       Impact factor: 4.981

Review 2.  Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.

Authors:  Angela K B Alme; Beerinder S Karir; Bishoy M Faltas; Charles G Drake
Journal:  Urol Oncol       Date:  2016-02-28       Impact factor: 3.498

Review 3.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

Review 4.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

Review 5.  Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances.

Authors:  Dung T Le; Elizabeth M Jaffee
Journal:  J Natl Compr Canc Netw       Date:  2013-07       Impact factor: 11.908

Review 6.  Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Authors:  Joseph A Fraietta; Robert D Schwab; Marcela V Maus
Journal:  Semin Oncol       Date:  2016-02-09       Impact factor: 4.929

7.  Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

Authors:  Claudia Marcela Diaz; Alberto Chiappori; Luigi Aurisicchio; Ansuman Bagchi; Jason Clark; Sheri Dubey; Arthur Fridman; Jesus C Fabregas; John Marshall; Elisa Scarselli; Nicola La Monica; Gennaro Ciliberto; Alberto J Montero
Journal:  J Transl Med       Date:  2013-03-08       Impact factor: 5.531

8.  Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.

Authors:  Daiqing Gao; Changyou Li; Xihe Xie; Peng Zhao; Xiaofang Wei; Weihong Sun; Hsin-Chen Liu; Aris T Alexandrou; Jennifer Jones; Ronghua Zhao; Jian Jian Li
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

Review 9.  Interleukin 12: still a promising candidate for tumor immunotherapy?

Authors:  Witold Lasek; Radosław Zagożdżon; Marek Jakobisiak
Journal:  Cancer Immunol Immunother       Date:  2014-02-11       Impact factor: 6.968

10.  Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Joachim Schmoll; Burghardt Wittig; Dirk Arnold; Jorge Riera-Knorrenschild; Dieter Nitsche; Hendrik Kroening; Frank Mayer; Johannes Andel; Reinhard Ziebermayr; Werner Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-10       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.